Guidant Profiting From Medtronic Rapid Exchange Exit
This article was originally published in The Gray Sheet
Executive Summary
Guidant is already reaping the benefit of Medtronic's pullout from the U.S. rapid-exchange delivery market and intends to build on its vascular intervention unit's strong financial performance in the third quarter going forward.
You may also be interested in...
Medtronic/MiniMed Insulin Pump Paradigm Aims To Grow 80% Market Share
Medtronic/MiniMed expects to boost its 80% share of the U.S. diabetes pump market with the Paradigm Model 511 insulin infusion system. A full-scale U.S. launch was announced Feb. 18
Medtronic/MiniMed Insulin Pump Paradigm Aims To Grow 80% Market Share
Medtronic/MiniMed expects to boost its 80% share of the U.S. diabetes pump market with the Paradigm Model 511 insulin infusion system. A full-scale U.S. launch was announced Feb. 18
Novoste Looking For “Deal-Maker” As CEO Hawkins Moves To Medtronic
Novoste will shift focus from leveraging core technologies and building a sales infrastructure to diversification and growth following the departure of CEO and President Bill Hawkins in mid-January to head Medtronic's vascular unit, Medtronic AVE